Capricor Therapeutics (NASDAQ:CAPR) Sees Large Volume Increase – Time to Buy?

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw unusually-high trading volume on Tuesday . Approximately 2,454,245 shares were traded during trading, an increase of 95% from the previous session’s volume of 1,258,353 shares.The stock last traded at $35.2190 and had previously closed at $30.63.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed review of Capricor’s Biologics License Application for Deramiocel and set a PDUFA target date of August 22, 2026 — this materially de-risks the program’s regulatory path and is the main catalyst for the recent rally. Capricor Announces Establishment of New PDUFA Date for Deramiocel BLA
• Positive Sentiment: Market coverage reports the stock surged on the FDA resumption—investors are pricing in upside from a successful BLA outcome and near-term clarity on a rare-disease cell therapy franchise. Capricor stock surges on FDA BLA review resumption
• Positive Sentiment: HC Wainwright reiterated a Buy rating and set a $60 price target (~78.7% above the recent price), providing additional analyst support that can attract momentum buyers and institutional interest. HC Wainwright Reiterates Buy Rating for Capricor Therapeutics
• Neutral Sentiment: Capricor is scheduled to post quarterly earnings soon — this timing may add short-term volatility but is not yet changing the core regulatory story. Capricor Projected to Post Quarterly Earnings
• Neutral Sentiment: Public short-interest data in recent filings appears anomalous (reported as 0 shares with NaN changes and a 0.0 days-to-cover), so there’s no clear evidence of a substantial short squeeze driving moves; treat those reports cautiously.
• Negative Sentiment: After the rapid run-up, some coverage highlights valuation risk and suggests the stock may be extended in the short term — investors should weigh the binary regulatory outcome against current implied upside. Assessing Capricor Valuation After Strong Short Term Share Price Run

Analyst Upgrades and Downgrades

CAPR has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Piper Sandler reiterated an “overweight” rating and issued a $45.00 price target (up from $20.00) on shares of Capricor Therapeutics in a research note on Wednesday, December 10th. Oppenheimer increased their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Capricor Therapeutics in a research report on Wednesday, January 14th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.82.

Capricor Therapeutics Stock Performance

The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -18.65 and a beta of 0.37. The business has a fifty day simple moving average of $25.57 and a 200 day simple moving average of $16.24.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock worth $73,936,000 after purchasing an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC bought a new stake in Capricor Therapeutics in the 4th quarter valued at about $51,533,000. Tang Capital Management LLC acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $49,062,000. RA Capital Management L.P. acquired a new position in shares of Capricor Therapeutics during the 4th quarter worth approximately $43,516,000. Finally, Geode Capital Management LLC increased its holdings in shares of Capricor Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after purchasing an additional 55,766 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.